Nectar Lifesciences Limited

Nectar Lifesciences Limited (NECLIFE) is a micro-cap Healthcare company valued at ₹205 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Nectar Lifesciences Limited last traded at ₹10.54, up 4.98% on the day.

Financial performance

The company's business has deteriorated significantly, with annual revenue collapsing by -100.0% and annual net profit turning into a loss that widened from ₹114 crore to ₹293 crore. The latest quarter shows a slight improvement in net profit, with the loss narrowing from ₹63 crore to ₹15 crore, but revenue remains at ₹0 crore, down -99.8% from the same quarter a year earlier.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 0.40 times book value.

Things to watch

The company is reporting a massive net loss of ₹293 crore, with the net profit margin plummeting to -14,650.0%. The return on equity and return on capital employed are both negative, at -50.3% and -8.9% respectively, indicating poor profitability. The net loss has widened over the past three years, from ₹24 crore to ₹293 crore.

Where it stands

Nectar Lifesciences Ltd is currently reporting a net loss of ₹293 crore, with the net profit margin at -14,650.0%. The company's return on equity and return on capital employed are both negative, and the net loss has widened significantly over the past three years. The latest quarter shows a narrowing loss, but revenue remains at ₹0 crore.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.